Showing results (441-450 of 460) with videos related to

Sort By:
Pageof 46
American Journal of Epidemiology|September 18, 1999
Risk factors for HIV-1 shedding in semenC E Speck, R W Coombs, L A Koutsky, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2012
Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ringM J Keller, A M Malone, C A Carpenter, et al.
The New England Journal of Medicine|April 18, 1996
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials GroupA C Collier, R W Coombs, D A Schoenfeld, et al.
The Journal of Infectious Diseases|August 11, 1998
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient dataJ P Ioannidis, A C Collier, D A Cooper, et al.
AIDS Research and Human Retroviruses|January 12, 2001
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1R Bures, A Gaitan, T Zhu, et al.
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|June 18, 2021
Feasibility of a Web-Accessible Game-Based Intervention Aimed at Improving Help Seeking and Coping Among Sexual and Gender Minority Youth: Results From a Randomized Controlled TrialJames E Egan, Stephanie L Corey, Emmett R Henderson, et al.
AIDS Research and Human Retroviruses|October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation GroupM C Keefer, M Wolff, G J Gorse, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 7, 1997
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremiaG Pantaleo, J F Demarest, T Schacker, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
Nature Medicine|June 17, 1999
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapyT W Chun, D Engel, S B Mizell, et al.
Pageof 46